Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F9 | P00740 | 6/20 | 0.42 |
| ▸ | F11 | P03951 | 14/20 | 0.42 |
| ▸ | KLK1 | P06870 | 3/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 8/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17480691 | 0.85 | F11 (0.54) | F11KLK1KLKB1 | |
| SCHEMBL17477800 | 0.85 | F11 (0.54) | F11KLK1KLKB1 | |
| SCHEMBL17480690 | 0.83 | F11 (0.42) | F9F11KLK1 | |
| SCHEMBL19253868 | 0.79 | F11 (0.48) | F9F11KLK1 | |
| SCHEMBL20953989 | 0.78 | F11 (0.57) | F9F11KLK1KLKB1 | |
| SCHEMBL20953990 | 0.78 | F11 (0.57) | F9F11KLK1KLKB1 | |
| SCHEMBL17480697 | 0.75 | F11 (0.44) | F9F11KLK1 | |
| SCHEMBL20979723 | 0.74 | F9 (0.52) | F9F11KLK1KLKB1 | |
| SCHEMBL17477821 | 0.74 | F11 (0.60) | F11KLK1KLKB1 | |
| SCHEMBL17477820 | 0.74 | F11 (0.60) | F11KLK1KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3180327-B1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME (US) | 2019-05-08 | — | — | EP | disclosed |
| EP-3180327-B1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME (US) | 2019-05-08 | — | — | EP | disclosed |
| US-10011585-B2 | Factor XIa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-07-03 | — | — | US | disclosed |
| US-10011585-B2 | Factor XIa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170240523-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-08-24 | — | — | US | disclosed |
| US-20170240523-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-08-24 | — | — | US | disclosed |
| WO-2016018701-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240523-A1 | FACTOR XIa INHIBITORS | F11, SERPINC1, TFPI | F9 16/4885F11 1/4885KLK1 24/4885 |
| US-10011585-B2 | Factor XIa inhibitors | F11, SERPINC1, TFPI | F9 16/4885F11 1/4885KLK1 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.